• Publications
  • Influence
Guideline for the management of clinically localized prostate cancer: 2007 update.
Ian Thompson (Chair),* James Brantley Thrasher (Co-Chair),† Gunnar Aus,‡ Arthur L. Burnett,§ Edith D. Canby-Hagino, Michael S. Cookson,¶ Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton,Expand
  • 1,110
  • 50
  • PDF
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update
PURPOSE The American Urological Association Prostate Guideline Update Panel was charged with updating the Guidelines for Clinically Localized Prostate Cancer. In assessing outcomes with treatment, itExpand
  • 566
  • 45
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy.
BACKGROUND To counsel patients adequately, it is important to understand the variables influencing satisfaction and regret following prostatectomy. OBJECTIVE To identify independent predictors forExpand
  • 314
  • 17
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
CONTEXT Recent studies have suggested that obese men have lower serum prostate-specific antigen (PSA) concentrations than nonobese men. Because men with higher body mass index (BMI) have greaterExpand
  • 308
  • 16
  • PDF
Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy.
PURPOSE We determined the incidence of patient self-reported post-prostatectomy incontinence, impotence, bladder neck contracture and/or urethral stricture, sexual function satisfaction, quality ofExpand
  • 223
  • 15
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.
Biologic effects of androgen on target cells are mediated in part by transcriptional regulation of androgen-regulated genes (ARGs) by androgen receptor. Using serial analysis of gene expressionExpand
  • 138
  • 14
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
PURPOSE To determine whether pretreatment risk groups shown to predict time to prostate cancer-specific mortality (PCSM) after treatment at a single institution retained that ability in aExpand
  • 442
  • 12
Prostate specific antigen only progression of prostate cancer.
  • J. Moul
  • Medicine
  • The Journal of urology
  • 1 June 2000
PURPOSE Introduction of the prostate specific antigen (PSA) serum marker for prostate cancer and the subsequent PSA era from 1988 to the present have dramatically altered the diagnosis of theExpand
  • 315
  • 11
  • PDF
The changing face of prostate cancer.
Prostate cancer remains the most common noncutaneous human malignancy, and the second most lethal tumor among men. However, the natural history of the disease is often prolonged, and the survivalExpand
  • 316
  • 11
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.
PSGR, a new prostate tissue-specific gene with homology to the G protein-coupled odorant receptor gene family, has been identified. Here we report the characteristics of the predicted proteinExpand
  • 174
  • 11
  • PDF
...
1
2
3
4
5
...